Beckman Coulter has become the latest diagnostics company to secure European regulatory clearance for a blood-based Alzheimer's biomarker assay, underscoring intensifying competition to supply scalable patient-selection tools as disease-modifying therapies expand. The CE Mark was awarded under IVDR for Beckman Coulter's Access p-Tau217 blood test, while the company simultaneously unveiled a companion research assay, the Access BD-pTau217, at the Alzheimer's Association International Conference (AAIC) 2026 in London. The CE-marked test measures phosphorylated tau 217 in blood samples to support clinical evaluation of amyloid pathology in patients showing signs of cognitive decline, marking the company's first regulatory-cleared, blood-based clinical assay for Alzheimer's-related pathology in Europe. The launch arrives as approved anti-amyloid therapies intensify demand for accessible patient stratification tools that can operate at scale beyond specialist imaging centres.
The Access p-Tau217 assay runs on Beckman Coulter's DxI 9000 Immunoassay Analyzer, a high-throughput, high-sensitivity platform already deployed in hospital and reference laboratory settings, allowing the test to slot into routine workflows without dedicated instrumentation. This addresses a persistent operational gap between specialist PET imaging or cerebrospinal fluid testing and scalable everyday clinical practice. The companion Access BD-pTau217 RUO assay targets a distinct biological signal — the short, low-molecular-weight form of brain-derived phosphorylated tau that originates specifically in the central nervous system — providing researchers with higher biological specificity to study tau staging and disease progression. Both assays run on the same DxI 9000 platform alongside existing RUO assays for GFAP, NfL, beta-amyloid 1-42, and apoE ε4.
The antibody underpinning the CE-marked assay was licensed from ALZpath and has been cited in more than 200 peer-reviewed publications, providing a substantial published evidence base ahead of commercial deployment. Independent validation from the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study of Ageing supports the BD-pTau217 RUO assay specifically, with researchers reporting that brain-derived pTau217 demonstrated additional biological specificity for tau-related staging when evaluated alongside amyloid and tau PET imaging. Beckman Coulter will present five posters at AAIC 2026, including late-breaking data on pTau217/Aβ42 and BD-Tau ratio approaches.
The blood-based Alzheimer's diagnostics market is increasingly competitive. Fujirebio and Roche both offer CE-marked or commercially available p-Tau217 or p-Tau181 immunoassays, with their Lumipulse and Elecsys platforms already established in European clinical laboratories. Beckman Coulter's differentiation rests on two factors: the ALZpath antibody's extensive published validation record, and the DxI 9000's ability to consolidate a broad neurodegenerative biomarker menu — spanning both clinical and research applications — onto a single high-throughput analyzer, reducing the instrumentation footprint laboratories must manage.